Re­lay builds out case for an­ti-FGFR drug, shoot­ing for first ac­cel­er­at­ed ap­proval on 'mo­tion-based' drug dis­cov­ery plat­form

Last Oc­to­ber, Re­lay Ther­a­peu­tics re­vealed ear­ly da­ta for its lead pro­gram, RLY-4008, hop­ing to build a case around a dif­fer­en­ti­at­ed safe­ty pro­file. Ear­ly Mon­day morn­ing, the biotech fol­lowed up with a more com­pre­hen­sive look at ef­fi­ca­cy, one it hopes will even­tu­al­ly sup­port an ac­cel­er­at­ed ap­proval.

Re­lay re­port­ed that eight of 13 evalu­able pa­tients across two dos­es in a form of bile duct can­cer achieved con­firmed par­tial re­spons­es, up from three of six in Oc­to­ber’s up­date. Ad­di­tion­al­ly, Re­lay said all four pa­tients treat­ed with the high­er dose ex­pect­ed to be used in the next study all had con­firmed PRs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER